NextCure, Inc.
(NASDAQ : NXTC)

( )
NXTC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.99%285.431.4%$838.91m
CELGCelgene Corp.
-1.09%108.131.3%$697.32m
AMGNAmgen, Inc.
1.74%224.501.3%$537.91m
GILDGilead Sciences, Inc.
1.10%65.001.0%$396.48m
VRTXVertex Pharmaceuticals, Inc.
2.38%215.001.9%$331.77m
ILMNIllumina, Inc.
1.42%311.013.5%$325.81m
REGNRegeneron Pharmaceuticals, Inc.
1.26%344.462.6%$271.28m
EXASEXACT Sciences Corp.
2.00%83.8024.0%$220.87m
ALXNAlexion Pharmaceuticals, Inc.
2.48%110.652.0%$184.62m
SGENSeattle Genetics, Inc.
1.86%117.886.1%$144.97m
BMRNBioMarin Pharmaceutical, Inc.
3.41%77.734.3%$132.55m
SRPTSarepta Therapeutics, Inc.
0.14%98.0414.6%$118.36m
AAgilent Technologies, Inc.
1.80%79.341.6%$101.34m
BGNEBeiGene Ltd.
4.03%203.902.1%$93.79m
NBIXNeurocrine Biosciences, Inc.
-1.67%112.735.0%$87.98m

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.